PT  - JOURNAL ARTICLE
AU  - McFerran, Ethna
AU  - Donaldson, Sarah
AU  - Lawler, Mark
TI  - Skin in The Game: The Cost Consequences of Skin Cancer Diagnosis, Treatment and Care in Northern Ireland
AID  - 10.1101/2023.05.09.23289720
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.09.23289720
4099  - http://medrxiv.org/content/early/2023/05/11/2023.05.09.23289720.short
4100  - http://medrxiv.org/content/early/2023/05/11/2023.05.09.23289720.full
AB  - Background Skin cancer is a prevalent type of cancer in the UK. Its rising incidence and mortality rates are expected to result in substantial financial implications, particularly on diagnostic and treatment services for skin cancer management in Northern Ireland. Such anticipated disease increases underscore the need for prevention and control measures that should guide policymaking and planning efforts.Methods We conducted a retrospective cost study to measure the burden of skin cancer in Northern Ireland from a healthcare system perspective. Our data-driven model utilized bottom-up methodology 1,2 and reported 2018 costs using NHS reference unit costs (UK£) for skin cancer diagnosis and treatment patient pathways. Sensitivity analyses were performed, including varying diagnostic volumes by applying multipliers for benign cases and assuming a diagnostic conversion rate of 6.8%. An alternative chemotherapy regimen compliance rate was also examined at 75% as compared to base case. Proportional increases were projected based on future estimated increases of 9% and 28% in melanoma cases for diagnostic, treatment, and follow-up volumes specifically related to malignant melanoma.Results As of 2018, NICR recorded 4142 non-melanoma skin cancers (NMSC) and 423 malignant melanoma (MM) cases, averaging 17.5 new patients per trust weekly. The total costs for managing NMSC was £1,815,936, whereas that for MM skin cancer costs was £12,364,220, out of which £8,792,208 accounted for procurement, administration, and chemotherapy drug use. Healthcare providers spent a total of £17,024,115 on skin cancer care. Sensitivity analysis suggest diagnostic cost would either reduce by £781k to £3,061,524 or increase significantly to £11,212,183 based on referral volume assumptions. If base case rates rise by 9 or 28% estimated total costs of treating skin cancer will increase to £18.1 million and £20.4 million respectively.Conclusions Skin cancer management costs in Northern Ireland vary from ∼£14.3m to £26.2m depending on diagnostic referral assumptions. Malignant melanoma costs have risen ∼10 fold over the past decade mainly due to chemotherapy costs. Predicted 28% increase in melanoma cases by 2040 would lead to £3.3m of additional referral, diagnostic and treatment expenditures, which with inflation adjustment to a further budget requirement of approximately £6.4 million by 2022 rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe primary author (EMF) was funded by grants from Cancer Focus Northern Ireland and Health Data Research UK. ML received grant funding from his roles as Associate Director of Health Data Research Wales-Northern Ireland and Scientific Director for DATA-CAN, The Health Data Research Hub for Cancer. The interpretation and conclusions of the data are the sole responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript